First Time in Human Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-23

Study Completion Date

2010-04-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male volunteers

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A First Time in Human Study of GSK586529 in Healthy Volunteers

NCT00703547

Depressive Disorder and Anxiety Disorders

COMPLETED PHASE1

First Study in Humans With GSK206136

NCT01059578

Depressive Disorder and Anxiety Disorders

COMPLETED PHASE1

Clinical Study to Test a New Drug to Treat Major Depression

NCT00976560

Depressive Disorder, Major

COMPLETED PHASE2

First Study in Humans With GSK424887

NCT01059591

Depressive Disorder and Anxiety Disorders

COMPLETED PHASE1

A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder

NCT00733980

Depressive Disorder, Major

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK356278 and may assess the effect of food on GSK356278 pharmacokinetics. They study will assess the compound's effect on nausea, emesis and alertness. Close monitoring of cardiovascular parameters will be included.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder and Anxiety Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1, Session 1

In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.

Group Type EXPERIMENTAL

GSK356278

Intervention Type DRUG

GSK356278

PLACEBO

Intervention Type DRUG

PLACEBO

Cohort 1, Session 2

In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.

Group Type EXPERIMENTAL

GSK356278

Intervention Type DRUG

GSK356278

PLACEBO

Intervention Type DRUG

PLACEBO

Cohort 1, Session 3

In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.

Group Type EXPERIMENTAL

GSK356278

Intervention Type DRUG

GSK356278

PLACEBO

Intervention Type DRUG

PLACEBO

Cohort 1, Session 4

In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.

Group Type EXPERIMENTAL

GSK356278

Intervention Type DRUG

GSK356278

PLACEBO

Intervention Type DRUG

PLACEBO

Cohort 1, Session 5

In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.

Group Type EXPERIMENTAL

GSK356278

Intervention Type DRUG

GSK356278

PLACEBO

Intervention Type DRUG

PLACEBO

Cohort 2, Session 1

In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.

Group Type EXPERIMENTAL

GSK356278

Intervention Type DRUG

GSK356278

PLACEBO

Intervention Type DRUG

PLACEBO

Cohort 2, Session 2

In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.

Group Type EXPERIMENTAL

GSK356278

Intervention Type DRUG

GSK356278

PLACEBO

Intervention Type DRUG

PLACEBO

Cohort 2, Session 3

In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.

Group Type EXPERIMENTAL

GSK356278

Intervention Type DRUG

GSK356278

PLACEBO

Intervention Type DRUG

PLACEBO

Cohort 2, Session 4

In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.

Group Type EXPERIMENTAL

GSK356278

Intervention Type DRUG

GSK356278

PLACEBO

Intervention Type DRUG

PLACEBO

Cohort 2, Session 5

In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.

Group Type EXPERIMENTAL

GSK356278

Intervention Type DRUG

GSK356278

PLACEBO

Intervention Type DRUG

PLACEBO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GSK356278

Intervention Type DRUG

PLACEBO

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* AST, ALT, alkaline phosphate and bilirubin less than or equal to 1.5 times upper limit of normal.
* Healthy as determined by a responsible and experienced physician based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
* Males aged between 18 and 65 years inclusive at the time of signing the informed consent.
* Males must agree to appropriate forms of contraception from administration of first dose through to 3 months after taking the final dose.
* Body weight greater than or equal to 50 kg and BMI within the range of 18-29.9 m2 (inclusive)
* Capable of giving written informed consent.
* QTcB or QTcF less than 450 msec

Exclusion Criteria

* A positive pre-study Hep B or positive Hep C result within 3 months of screening.
* Current or chronic history of liver disease or known hepatic or biliary abnormalities
* A positive pre-study alcohol and drug screen
* A positive test for HIV antibody.
* History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units or average daily intake of greater than 3 units
* The subject has participated in a clinical trial and has received investigational product within the time period of 30 days prior to first dosing day (or 5 half-lives or twice the duration of the biological effect of the drug, whichever is longer)
* Exposure to more than 4 new chemical entities in the last 12 months prior to the first dosing day
* Use of prescription or non-prescription drugs including vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose unless in the opinion of the investigator and medical monitor the medication will not interfere with the study procedures or compromise subject safety.
* History of sensitivity to any of the study medication or history of drug or other allergy that in the opinion of the investigator or medical monitor contraindicates their participation.
* Where participation in the study would result in donation of blood or blood products in excess of 500 ml within a 56 day period.
* Unwillingness or inability to follow the procedures in the protocol.
* Subject is mentally or legally incapacitated.
* Subjects who have asthma or a history of asthma.
* Urinary cotinine levels indicative of smoking or history of regular use of tobacco or nicotine containing products within 6 months prior to screening.
* Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose.
* History of any significant psychiatric illness.
* Any history of suicidal behaviour or any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale in the last 6 months.
* History of presence of clinically significant cardiac arrhythmias or other clinically significant cardiac disease.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Randwick, New South Wales, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.